chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Injection site swelling; Injection site pain; Tiredness; Headache; Muscle pain; Chills; Fever; Joint pain; Vomiting; Dizziness; Overall fatigue; Ddehydration; This is a spontaneous report from a non-contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm right on 12Apr2021 at 12:15 hours (at the age of 68-year-old) as a single dose for COVID-19 immunisation. The patient received unspecified medication within two weeks of vaccination. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm right on 24Mar2021 at 12:15 hours (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 14:00 the patient experienced dehydration, injection site swelling, injection site pain, tiredness, headache, muscle pain, chills, fever, joint pain, vomiting, dizziness and overall fatigue. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events dehydration, injection site swelling, injection site pain, tiredness, headache, muscle pain, chills, fever, joint pain, vomiting, dizziness and overall fatigue was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Myalgia, Pyrexia
Clinical narrative: Muscle pain; joint pain; headaches; mild fever; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 02Apr2021 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Patient had no other medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 11Mar2021 at 00:15 (at the age of 35-years-old) as a single dose for COVID-19 immunisation.  Concomitant medications included ibuprofen sodium (IBUPROFEN) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 07:00,  the patient experienced muscle pain, joint pain, headaches, mild fever up to 37.2 centigrade for 11 days after the second shot. Pain in knee joints and leg muscles was still persistent 14 days after the second shot. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events of muscle pain and joint pain which included treatment with ibuprofen 400mg (2x per day) to sooth the pain. On 14Apr2021, 12th day after the second shot, the patient underwent erythrocyte sedimentation rate by modified westergren and the result was 43 mm/h (norm is <OR = 15) and the C- reactive protein test was also done and the result was 53.7 mg/l (norm is <8.0 mg/L). On 03Apr2021, the patient underwent body temperature  check and the result was 37.2 centigrade.  Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events of muscle pain and  joint pain was recovering while events of  headaches, mild fever was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Vascular pain, Vasodilatation
Clinical narrative: May be 28 minutes after taking shot left ring finger top joint felt pain and felt like a slight burn.; May be 28 minutes after taking shot left ring finger top joint felt pain and felt like a slight burn.; When looked at finger, saw the vein popping in upper part of finger vertically. The patient started to rub it because it hurt; When looked at finger, saw the vein popping in upper part of finger vertically. The patient started to rub it because it hurt; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO153), via an unspecified route of administration in the left arm on 06Apr2021 at 11:45 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. Medical history included mild asthma, osteoarthritis in both knees, insomnia, low vitamin d and latex allergy. Concomitant medications included doxylamine succinate (UNISOM), vitamin d nos (VITAMIN D), minerals nos, vitamins nos, xantofyl (KIRKLAND ADULT GUMMIES) and hylan g-f 20 (SYNVISC ONE); all from unknown dates for unspecified indications. The patient previously took rofecoxib (VIOXX), cox-2 drugs for example celecoxib (CELEBREX), aspartame (MANUFACTURER UNKNOWN); all on unknown dates for unspecified indications and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 12:30, the patient waited 15 minutes after receiving shot at pharmacy clinic and may be 28 minutes later after taking the shot, the patient experienced left ring finger top joint felt pain and felt like a slight burn, like when one touch a hot light bulb quickly. When the patient looked at finger, saw the vein popping in upper part of finger vertically. The patient started to rub it because it hurt and 5 to 6 minutes later vein popping went away and most of pain, then may be another minute for all pain to go away. The events did not result in doctor or other health care professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events left ring finger top joint felt pain, vein popping in upper part of finger vertically, started to rub it because it hurt were resolved on 06Apr2021. The clinical outcome of the event felt like a slight burn was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Test: Nasal Swab/Result: Positive; This is a spontaneous report from a contactable consumer (patient) or other non hcp. A 31-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported and expiry date: unknown), dose 1 via an unspecified route of administration, administered in Arm Left on 06Jan2021 at 11:30 as DOSE 1, SINGLE for covid-19 immunisation. Medical history included sleep apnoea syndrome, food allergy (shellfish). There were no concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced test: nasal swab/result: positive on 12Jan2021. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 12Jan2021. Outcome of the event was unknown.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, Lip pain, Lip swelling
Clinical narrative: lip swelling; rapid heart rate; Sensitivity of lips; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6205) via an unspecified route of administration in the right arm on 10Apr2021 at 09:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medications in two weeks of vaccine. The patient previously took nonsteroidal anti-inflammatory drugs (NSAIDs) (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced allergic reactions to analgesics. The patient previously took oral steroids (MANUFACTURER UNKNOWN) used for prior allergic events and was avoiding so that it will not impact on her immunity. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206) via an unspecified route of administration in the right arm on 17Mar2021 at 16:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 18:00, 36 hours post vaccination, the patient experienced sensitivity of lips. On 13Apr2021, 3-1/2 days post vaccination, the patient experienced rapid heart rate. On 15Apr2021, 5 days post vaccination, the patient experienced lip swelling. Therapeutic measures were taken as a result of adverse events which included treatment with antihistamines. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sensitivity of lips, rapid heart rate and lip swelling was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dry mouth, Dyspnoea, Fatigue, Headache
Clinical narrative: Itching at the site of the vaccine injection; tingling/itching sensation on lips; tingling/itching sensation on lips; Tightness in chest; difficulty breathing; All over body soreness pain in legs and feet; Sore and itchy throat; dry mouth; Runny nose; sneezing; headache; Very tired and sore slept for 16+ hours; Sore and itchy throat; All over body soreness pain in legs and feet; All over body soreness pain in legs and feet; This is a spontaneous report from a contactable consumer or other non hcp (patient reported for herself). A 19-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: FW0162), via an unspecified route of administration, administered in arm left on 14Apr2021 at 10:00 AM (at the age of 19-year-old) as dose 1, single for COVID-19 immunization. The patient medical history included asthma (had to administer Pro-Air Asthma medication multiple times) from an unknown date and unknown if ongoing. Patient had no known allergies. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within four weeks. Patient was not diagnosed with COVID prior vaccination. Patient was not COVID tested post vaccination. On 14Apr2021 at 13:30 (01:30 PM), the patient experienced itching at the site of the vaccine injection, tingling/itching sensation on lips, tightness in chest, difficulty breathing, all over body soreness pain in legs and feet, sore and itchy throat, dry mouth, runny nose, sneezing, headache, very tired and sore slept for 16+ hours. Adverse event: Itching at the site of the vaccine injection and tingling/itching sensation on lips. Tightness in chest and difficulty breathing. Had to administer Pro-Air Asthma medication multiple times. All over body soreness pain in legs and feet. Sore and itchy throat, very dry mouth. Runny nose, sneezing, may have caused headache. Very tired and sore slept for 16+ hours. The patient received treatment for the events tightness in chest, difficulty breathing. Outcome of the events was recovering.  Follow-Up (PRD/SRD 18Aug2021): Follow-up attempts are completed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Lip pruritus, Oropharyngeal pain, Pain, Pain in extremity, Paraesthesia oral
Clinical narrative: Itching at the site of the vaccine injection; tingling/itching sensation on lips; tingling/itching sensation on lips; Tightness in chest; difficulty breathing; All over body soreness pain in legs and feet; Sore and itchy throat; dry mouth; Runny nose; sneezing; headache; Very tired and sore slept for 16+ hours; Sore and itchy throat; All over body soreness pain in legs and feet; All over body soreness pain in legs and feet; This is a spontaneous report from a contactable consumer or other non hcp (patient reported for herself). A 19-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: FW0162), via an unspecified route of administration, administered in arm left on 14Apr2021 at 10:00 AM (at the age of 19-year-old) as dose 1, single for COVID-19 immunization. The patient medical history included asthma (had to administer Pro-Air Asthma medication multiple times) from an unknown date and unknown if ongoing. Patient had no known allergies. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within four weeks. Patient was not diagnosed with COVID prior vaccination. Patient was not COVID tested post vaccination. On 14Apr2021 at 13:30 (01:30 PM), the patient experienced itching at the site of the vaccine injection, tingling/itching sensation on lips, tightness in chest, difficulty breathing, all over body soreness pain in legs and feet, sore and itchy throat, dry mouth, runny nose, sneezing, headache, very tired and sore slept for 16+ hours. Adverse event: Itching at the site of the vaccine injection and tingling/itching sensation on lips. Tightness in chest and difficulty breathing. Had to administer Pro-Air Asthma medication multiple times. All over body soreness pain in legs and feet. Sore and itchy throat, very dry mouth. Runny nose, sneezing, may have caused headache. Very tired and sore slept for 16+ hours. The patient received treatment for the events tightness in chest, difficulty breathing. Outcome of the events was recovering.  Follow-Up (PRD/SRD 18Aug2021): Follow-up attempts are completed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea, Sneezing, Throat irritation, Vaccination site pruritus
Clinical narrative: Itching at the site of the vaccine injection; tingling/itching sensation on lips; tingling/itching sensation on lips; Tightness in chest; difficulty breathing; All over body soreness pain in legs and feet; Sore and itchy throat; dry mouth; Runny nose; sneezing; headache; Very tired and sore slept for 16+ hours; Sore and itchy throat; All over body soreness pain in legs and feet; All over body soreness pain in legs and feet; This is a spontaneous report from a contactable consumer or other non hcp (patient reported for herself). A 19-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: FW0162), via an unspecified route of administration, administered in arm left on 14Apr2021 at 10:00 AM (at the age of 19-year-old) as dose 1, single for COVID-19 immunization. The patient medical history included asthma (had to administer Pro-Air Asthma medication multiple times) from an unknown date and unknown if ongoing. Patient had no known allergies. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within four weeks. Patient was not diagnosed with COVID prior vaccination. Patient was not COVID tested post vaccination. On 14Apr2021 at 13:30 (01:30 PM), the patient experienced itching at the site of the vaccine injection, tingling/itching sensation on lips, tightness in chest, difficulty breathing, all over body soreness pain in legs and feet, sore and itchy throat, dry mouth, runny nose, sneezing, headache, very tired and sore slept for 16+ hours. Adverse event: Itching at the site of the vaccine injection and tingling/itching sensation on lips. Tightness in chest and difficulty breathing. Had to administer Pro-Air Asthma medication multiple times. All over body soreness pain in legs and feet. Sore and itchy throat, very dry mouth. Runny nose, sneezing, may have caused headache. Very tired and sore slept for 16+ hours. The patient received treatment for the events tightness in chest, difficulty breathing. Outcome of the events was recovering.  Follow-Up (PRD/SRD 18Aug2021): Follow-up attempts are completed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Pain in extremity, Vaccination site pain
Clinical narrative: pain around the area of vaccine; pain in arm; pain in shoulder; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient was allergic to sulphur. On 24Mar2021, the patient experienced pain around the area of vaccine and pain in shoulder and arm. Therapeutic measures were not taken as a result of the events. The clinical outcome for the events pain around the area of vaccine and pain in shoulder and arm was unknown at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN608) via an unspecified route of administration in the left arm on 14Apr2021 as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: I developed a cold sore a few days after each dose.; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 04Mar2021 at 14:30 (at the age of 45-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 25Mar2021 at 14:30 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. The patient medical history was not reported. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, the patient developed a cold sore a few days after each dose. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event cold sore a few days after each dose was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: This is a spontaneous report from a contactable consumer or other non-HCP. A 59-year-old female patient received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; solution for injection batch/lot# EW0150), via an unspecified route of administration, administered in left arm, on Apr 12, 2021, 13:45, single dose, for COVID-19 immunisation. Medical history not reported. Concomitant medication(s) included tamoxifen. The patient previously took prednisone and experienced drug hypersensitivity. The patient did not receive any other vaccine in four weeks. Prior to vaccination patient was not diagnosed with COVID-19. Reportedly, patient tested negative for COVID-19 3 days before receiving the vaccine and then tested positive for COVID-19 2 days after receiving the vaccine on Apr 14, 2021, with outcome of recovering. The patient underwent lab tests and procedures, which included SARS-CoV-2 test: negative on Apr 9, 2021; and SARS-CoV-2 test: positive on Apr 14, 2021. No follow-up attempts possible. No further information expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable pharmacist, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK9231) via an unspecified route of administration in the left arm on 28Jan2021 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EJ1685) via an unspecified route of administration in the right arm on 07Jan2021 (at the age of 55-year-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Feb2021 the patient experienced tinnitus. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event tinnitus was not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Vomiting
Clinical narrative: Dizziness; vomiting; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included cetirizine (MANUFACTURER UNKNOWN) from an unknown date for allergy. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not take any other vaccine in four weeks. On 13Apr2021, the patient experienced dizziness and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events dizziness and vomiting was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Cold sweat, Paraesthesia
Clinical narrative: tingling/pins and needles in both hands and fingers and scalp; cold sweat; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration on an unknown date in Apr2021 at 16:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, hashimoto's disease, pre-diabetic, and drug allergy (Liver inflammation with certain meds). Concomitant medications included fluoxetine hydrochloride (PROZAC) 10 mg. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 16:30 the patient experienced tingling/pins and needles in both hands and fingers and scalp, cold sweat. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events tingling/pins and needles in both hands and fingers and scalp, cold sweat was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: LOW grade fever for five days now; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Apr2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had non known allergies to medications, food or other products. The patient did not receive any concomitant medications. The patient previously received the first dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 19:00, the patient experienced LOW grade fever for five days now. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event LOW grade fever for five days now was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Within 24 hrs of vaccinations I get nosebleeds usually late at night or early morning; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 12Apr2021 at 12:45 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 infection. The patient had no known allergies. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 19Mar2021 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient experienced nose bleed which lasted for 4 days. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 13Apr2021 at 11:30 the patient experienced nosebleeds within 24 hours of vaccination usually late at night or early morning. They were sudden and took 10 min to usually stop. No therapeutic measures were taken as a result of adverse event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event nosebleeds was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lethargy, Muscular weakness
Clinical narrative: Lethargy; Headache; Muscle weakness; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 12Apr2021 at 15:15 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia. Concomitant medications included pregabalin (LYRICA), duloxetine hydrochloride (CYMBALTA), butalbital, caffeine, paracetamol (FIORICET) and norethisterone acetate (NORETHINDRONE) on unknown date for unspecified indication. The patient had no allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 23:00, the patient experienced lethargy, headache and muscle weakness. No therapeutic measures were taken as a result of all the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events lethargy, headache and muscle weakness were recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: under arm lymph node swollen; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 14Apr2021 at 11:45 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, degenerative disc disease, spinal stenosis, irritable bowel syndrome (IBS), sulfonamide allergy and vegetable allergy (tomatoes and broccoli).  Concomitant medications included meloxicam (MANUFACTURER UNKNOWN), pregabalin (LYRICA), escitalopram oxalate (LEXAPRO) and vitamin d nos (MANUFACTURER UNKNOWN) on unknown date for unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 24Mar2021 at 12:15 (at the age of 48-year-old) as a single dose for COVID-19 immunisation and took levofloxacin (LEVAQUIN), duloxetine hydrochloride (CYMBALTA), clavulanate potassium; amoxicillin trihydrate (AMOXICLAV), sulfur (MANUFACTURER UNKNOWN); all on unknown date for unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 00:00 the patient experienced under arm lymph node swollen. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient did not receive any treatment for the events.  The clinical outcome of the event under arm lymph node swollen was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pyrexia
Clinical narrative: Fatigue; fever; This is a spontaneous report from a contactable other healthcare professional, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on an unknown date in Apr2021 at 15:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no allergic to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021, the patient underwent nasal swab test and the result was negative. On 02Apr2021 at 16:00, the patient experienced fatigue and fever of 101F. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fatigue and fever was resolved in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 26-year-old (non-pregnant)  female patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 26, via an unspecified route of administration, left arm, on Apr 15, 2021, at 16:45, single dose, for COVID-19 immunisation. Medical history not reported. The patient did not receive any concomitant medications. The patient is allergic to sulfa. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 15, 2021, at 17:00, 45 minutes after injection, patient felt her lips and face became numb and were still partially numb the next day. Therapeutic measures not taken as a result of these events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of numbness in face and lips: recovered, with sequelae on an unknown date in Apr 2021. No follow-up attempts needed. Information about lot/batch number cannot be obtained.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Myalgia, Nausea
Clinical narrative: Arm site pain; Muscle aches; Joint pain; Nausea; Headache; Tired; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 13Apr2021 at 09:00(at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy, migraine and COVID-19. Concomitant medications included vitamin d nos (VITAMIN D), fexofenadine hydrochloride, pseudoephedrine hydrochloride (ALLEGRA D), multi-vitamin (MANUFACTURER UNKNOWN) and aluminium hydroxide, magnesium hydroxide (MAGNESIUM) for unknown indication from an unknown date. The patient previously received Keflex (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 12:00, the patient experienced arm site pain, muscle aches, joint pain, nausea, headache and tired. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm site pain, muscle aches, joint pain, nausea, headache and tired were not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm site pain; Muscle aches; Joint pain; Nausea; Headache; Tired; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 13Apr2021 at 09:00(at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy, migraine and COVID-19. Concomitant medications included vitamin d nos (VITAMIN D), fexofenadine hydrochloride, pseudoephedrine hydrochloride (ALLEGRA D), multi-vitamin (MANUFACTURER UNKNOWN) and aluminium hydroxide, magnesium hydroxide (MAGNESIUM) for unknown indication from an unknown date. The patient previously received Keflex (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 12:00, the patient experienced arm site pain, muscle aches, joint pain, nausea, headache and tired. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm site pain, muscle aches, joint pain, nausea, headache and tired were not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain
Clinical narrative: Headache; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 09Apr2021 at 17:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if its ongoing. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 13:00, the patient experienced headache and body aches. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache and body aches was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Pyrexia, SARS-CoV-2 test
Clinical narrative: Low fever; Fatigue; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 11Apr2021 at 12:45(at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included treatment for breast cancer and the patient had adhesive allergy. Concomitant medications included paclitaxel (MANUFACTURER UNKNOWN), loperamide hydrochloride (IMODIUM), diphenhydramine/ paracetamol/ phenylpropanolamine hydrochloride (BENADRYL), trastuzumab (MANUFACTURER UNKNOWN) and plochl (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 21Mar2021 at 12:45 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 09:00, the patient experienced low fever, fatigue and joint pain. Therapeutic measures were taken as a result of events included treatment with ibuprofen (MOTRIN) and paracetamol (TYLENOL) for fever. On 13Apr2021, the patient underwent nasal swab (Sars-CoV2 test) and the result was negative. The clinical outcome of the events low fever, fatigue and joint pain was recovered in the year Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Lip swelling, Urticaria
Clinical narrative: hives; lip swelling; This is a spontaneous report from a contactable physician. A 23-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14Apr2021 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medication within 2 weeks of vaccination. On 14Apr2021 the patient experienced hives and lip swelling. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as the result of adverse events and included treatment with corticosteroid and antihistamines. The clinical outcome of the events hives and lip swelling were resolving at the time of report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Hypersomnia, Movement disorder, Vomiting
Clinical narrative: Couldnt keep anything down.; 5 hours after receiving the 2nd dose had a headache; vomiting every hour; Spent sleeping; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 08Apr2021 at 15:15 (at the age of 57-year-old) as a single dose for COVID-19 immunization. Medical history included asthma since unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) on an unspecified date for an unknown indication and experienced drug allergy. Concomitant medications included ADVAIR (MANUFACTURER UNKNOWN since unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 11Mar2021 at 15:15 (at the age of 57-year-old) as a single dose for COVID-19 immunization. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 20:00, 5 hours after receiving the 2nd dose the patient had headache and at 7 hours vomited., rest of the night was spent with a horrible headache and vomiting every hour, couldn't keep anything down. On an unknown date in Ap2021 (next day) spent sleeping, next day woke up with headache still had headache, next morning woke up with headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the reported adverse events, however the patient took Tylenol for the headache. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache and at 7 hours vomited, rest of the night was spent with a horrible headache and vomiting every hour, couldn't keep anything down, spent sleeping was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Flu-like symptoms; This is a spontaneous report from a non-contactable consumer. A non-pregnant female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on an unknown date in Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. . The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 the patient experienced flu-like symptoms. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown if patient received treatment for the events. The clinical outcome of the event flu-like symptoms was recovered on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Nausea, Pyrexia
Clinical narrative: Fever, nausea 1 hour of getting shot.That evening chills; nausea 1 hour of getting shot; that evening chills; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8737) via an unspecified route of administration in the right arm on 14Apr2021 at 16:00(at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure was little high and penicillin allergy. Concomitant medications included hydrochlorothiazide, lisinopril (LISINOPRIL/HCTZ) and amlodipine (MANUFACTURER UNKNOWN); both for unspecified indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 14Apr2021 at 17:15, the patient after one hour of shot, experienced fever, nausea and that evening chills. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event fever, nausea and chills was recovered on an unknown date in 2021, at the time of this report.  No follow-up attempts are needed. No further information is expected.